Abstract
Background Multimorbidity, especially among older patients, is one of the biggest challenges faced by modern medicine, and is influenced by social determinants of health, giving rise to health inequalities in the population. Here, we sought to determine the influence of social determinants of health on quality of life in patients with multimorbidity.
Methods and Materials This cross-sectional observational study included 573 patients aged 65–74 with multimorbidity (≥3 diseases) and polypharmacy (≥5 drugs). Corresponding data was taken drawn from the Spanish MULTIPAP study, and included social and demographic variables, and data on health-related quality of life and overall self-perceived health status, assessed using the 5-level version of the EuroQol 5-dimensional questionnaire (EQ-5D-5L). Descriptive, bivariate and multivariate analyses with logistic regression models were performed.
Results Mean patient age was 69.7 years, 55.8% of patients were female, 59.7% belonged to low social classes (V, VI), a monthly income of 1051–€1850 predominated, and the median number of diseases in the same patient was 6. Factors associated with higher quality of life were male gender (OR=1.599, p=0.013), a higher educational level (OR=1.991, p=0.036), an absence of urban vulnerability (OR=1.605, p=0.017), and the presence of medium social support (OR=1.689, p=0.017). Having a higher number of diseases was associated with poorer quality of life (OR=0.912, p=0.017).
Conclusions Our findings describe associations between social determinants of health and quality of life in patients aged 65–74 years with multimorbidity and polypharmacy. More illnesses, female gender, a lower education level, urban vulnerability, and less social support are associated with poorer quality of life, underscoring the need for a biopsychosocial approach in patient care.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Clinical Research Ethics Committees of Aragón (CEICA, PI15/0217) and was favourably evaluated by the Research Ethics Committee of the Province of Malaga and by the Central Committee of Primary Care Research of the Community of Madrid. The recruiting physicians provided the patient with detail information about the study, they confirmed the patient's eligibility and obtained the patient's written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵¥ Membership of the MULTIPAP GROUP is provided in the Acknowledgments
Data availability
The Aragon Ethics Committee approved this research without considering the option of data sharing. The data include sensitive clinical information about patients, and there are therefore ethical and legal restrictions to sharing the data set. The data are part of the MULTIPAP study and can be requested by contacting the Aragon Ethics Committee at the email address ceica{at}aragon.es. Data can also be requested by contacting the Primary Care Management of Madrid at the email address gap{at}salud.madrid.org, and the Technical Direction of Teaching and Research at the email address dtdei{at}salud.madrid.org. The MULTIPAP Group may establish future collaborations with other groups based on the same data. Data will be available from the authors upon reasonable request and with permission of the project’s principal investigators (Alexandra Prados-Torres: sprados.iacs{at}aragon.es; Daniel Prados-Torres: juand.prados.sspa{at}juntadeandalucia.es; Isabel del Cura: isabel.cura{at}salud.madrid.org). However, each new project based on these data must be first submitted to CEICA for approval.
